GSK closed up 8% today, which is a very large move for a Big Pharma. Alas, most of today’s move was probably from the swine-flu hysteria rather than the more consequential news about Avodart.
Even though Avodart goes off-patent in 2015, if the patent is not knocked out earlier by Teva’s challenge, GSK might earn $2B+ in cumulative incremental revenue from Avodart sales in cancer prevention. I highly doubt that GSK will earn anything close to this amount from swine flu.